Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Routine FFR/iFR Reclassifies Treatment Strategies in Half of Cases

Routine invasive physiology assessment at time of angiography reclassifies treatment strategies in a big number of patients with lesions in 2 or 3 vessels, according to the multicenter prospective study DEFINE REAL, recently published in JACC Cardiovascular Interventions.

El FFR/iFR rutinario reclasifica la estrategia de tratamiento en casi la mitad de los casos

The information obtained by measuring fractional flow reserve (FFR) or instantaneous wave free ratio (iFR) made interventionists modify their original plans in 45% of cases. Reclassification was higher as more vessels were assessed, reaching an astonishing 66.7% for cases when 3 epicardial vessels were assessed.


Leia também: DEFINE FLAIR and IFR SWEDEHEART: Safety in Revascularization Based on FFR and iFR in Both Stable and ACS Patients.


These findings now published in JACC had been originally presented at EuroPCR and are consistent with prior studies (R3F, RIPCORD, POST-IT), though these mostly included patients with one vessel disease. DEFINE REAL is the first invasive physiology study to focus on patients with multivessel disease.

 

The message is loud and clear and, at the same time, challenging: invasive physiology study of all vessels is mandatory, even in patients with non-invasive tests suggesting ischemia prior catheterization. In turn, this raises the question: does the change of strategy convey a change in prognosis?

 

DEFINE REAL was carried out in 18 centers across 9 countries and included 484 patients with multivessel disease undergoing diagnostic angiography (73.3% presented 2 vessel disease, and 26.7% 3 vessel disease).


Leia também: What Is the Long-Term Outcome of Lesions Deferred Using FFR/iFR?


Researchers first defined an initial strategy based on  angiography and clinical assessment, then performed a physiology assessment, one third with iFR and the rest with FFR, and the final strategy was defined.

 

The change of plans, thanks to FFR/iFR, increased the use of medical treatment and myocardial revascularization surgery and modestly reduced the use of PCI.

 

The use of iFR was associated with less symptoms and the chance to assess more vessels, which resulted in a higher rate of reclassification than that obtained with the use of FFR (57.5% vs 39.9%).


Leia também: Surprisingly, some patients won’t do as told and have less events.


This study does not provide any information on clinical results, which remains to be sorted out by future studies. For now, the best we have are the SYNTAX II outcomes, published last year, which showed physiology assessment had very good results.

 

Título original: Impact of routine invasive physiology at time of angiography in patients with multivessel coronary artery disease on reclassification of revascularization strategy: results from the DEFINE REAL study.

Referencia: Van Belle E et al. J Am Coll Cardiol Intv. 2018;11:354-365.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Sua opinião nos interessa. Pode deixar abaixo seu comentário, reflexão, pergunta ou o que desejar. Será mais que bem-vindo.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...